Aptabio s Isuzinaxib (APX-115) proves its effect on a key kidney function marker in a Phase 2 clinical study in patients with diabetes and chronic kidney.
Share this article
Share this article
ResearchAndMarkets.com s offering.
Report Highlights
The Parkinson s Disease (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Parkinson s Disease and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 3, 11, 48, 62, 4, 224, 97 and 9 respectively. Similarly, the Universities portfolio in Phase III, Phase II, Phase I, Preclinical and Discovery stages comprises 1, 1, 1, 52 and 19 molecules, respectively.
The Parkinson s Disease (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter-strategies to gain competitive adva